|RAS082-C01||Pre-coated Anti-SARS-CoV-2 Spike RBD (B.1.1.529) Antibody Microplate||1 plate|
|RAS082-C02||SARS-CoV-2 Spike RBD (B.1.1.529)||10 μg|
|RAS082-C03||HRP-Anti-SARS-CoV-2 Spike RBD Antibody||20 μg|
|RAS082-C04||10xWashing Buffer||50 mL|
|RAS082-C05||Dilution Buffer||50 mL|
|RAS082-C06||Substrate Solution||12 mL|
|RAS082-C07||Stop Solution||7 mL|
The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Your experiment will include 5 simple steps:
a) All reagents were returned to room temperature(20℃-25℃) before use.
b) Add your sample to the plate, take the SARS-CoV-2 Spike RBD as Control sample. The samples and Control sample are diluted by Dilution Buffer.
c) Add a diluted HRP-Anti-SARS-CoV-2 Spike RBD Antibody to the plate. The diluted by Dilution Buffer.
d) Wash the plate and add TMB.
e) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculate as the absorbance at 450 nm minus the absorbance at 630 nm to remove background prior to statistical analysis. The OD Value reflects the amount of protein bound.
Detection of Monoclonal SARS-CoV-2 Spike RBD (B.1.1.529) titer by sandwich-ELISA Assay.
Immobilized Anti-SARS-CoV-2 Spike RBD (B.1.1.529) Antibody at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 Spike RBD (B.1.1.529). Detection was performed using HRP-Anti-SARS-CoV-2 Spike RBD Antibody with sensitivity of 4 ng/mL (QC tested).
SARS-CoV-2 Spike RBD (B.1.1.529) Specific ELISA Kit (For Vaccine Development)(Cat.No.RAS-A082) can specifically detect Omicron(SPD-C522e),cannot detect other strains,inchuding WT、Alpha、Beta、Gamma and Delta.
Price(USD) : $780.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.